Text this: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

   _____   _    _     _  _     ______    _____   
  / ___// | || | ||  | \| ||  /_   _//  / ____|| 
  \___ \\ | || | ||  |  ' ||   -| ||-  / //---`' 
  /    // | \\_/ ||  | .  ||   _| ||_  \ \\___   
 /____//   \____//   |_|\_||  /_____//  \_____|| 
`-----`     `---`    `-` -`   `-----`    `----`